feedback

Course Directors

Jason J. Luke, MD, FACP
Jason J. Luke, MD, FACP

The University of Chicago
Chicago, Illinois

Jennifer Wargo, MD, MMSc
Jennifer Wargo, MD, MMSc

The University of Texas MD Anderson Cancer Center
Houston,Texas

Faculty

Jennifer Tseng
Jennifer Tseng, MD

The University of Chicago
Chicago, Illinois

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:1.0 Credits
Release Date:2019-Apr-25
Expiration Date:2020-Apr-24
Estimated Time for Completion:60 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

Melanoma was the first clinical setting in which the use of immune checkpoint inhibitors was validated, leading to their rapid integration into the management of advanced disease. More recently, checkpoint inhibitors, based on phase 3 evidence, have claimed a role in the adjuvant setting. The future of adjuvant therapy for high-risk resectable melanoma is bright, but achieving optimal care will depend on close collaboration between oncologists and surgeons, as well as the identification of patients who are excellent candidates for immune-based adjuvant therapy. In this activity, based on a recent live symposium, experts in oncology get to the heart of why immunotherapy is a rational and potent management strategy for patients with high-risk, resected melanoma, offer insights into the key studies that validated adjuvant immunotherapy in resectable disease, as well as clarify what the evidence from these trials means for the practice of surgical oncology. The panel of leading experts also synthesizes the clinical experience with adjuvant checkpoint inhibition and detail practical patient identification, dosing, and safety considerations that will make a difference in how you manage your patients.

Upon completion of this activity, participants should be better able to:
  • Describe the clinical role and rationale for use of immune-based therapy in stage III, resectable melanoma
  • Cite updated efficacy and safety findings regarding immune checkpoint inhibitors as an adjuvant option in surgically resected melanoma, including high-risk stage III disease
  • Recommend the use of adjuvant immunotherapy for eligible patients with resectable stage III melanoma
  • Manage immune-related and immune-mediated adverse events in patients with melanoma treated with immunotherapy after surgical resection

Target Audience

This activity has been designed to meet the educational needs of surgical oncologists, medical oncologists, and other clinicians involved in the management of melanoma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: April 25, 2019 - April 24, 2020
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Other PVI associates who are in a position to have control over the content of this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

The associates of the Medical Learning Institute, Inc., the accredited provider for this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Course Directors

Jason J. Luke, MD, FACP
Assistant Professor of Medicine
Section of Hematology/Oncology
The University of Chicago
Chicago, Illinois

Jason J. Luke, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for 7 Hills Pharma LLC; Actym Therapeutics, Inc.; Aduro Biotech; Alphamab Oncology; Array BioPharma; AstraZeneca; Benevir Biopharm Inc.; Bristol-Myers Squibb; Castle Biosciences, Inc.; Checkmate Pharmaceuticals; Compugen Ltd.; EMD Serono, Inc.; Ideaya Biosciences; Janssen Pharmaceuticals, Inc.; Mavupharma; Merck & Co., Inc.; NewLink Genetics Corporation; Novartis Pharmaceuticals Corporation; Reflexion Pharmaceuticals, Inc.; Spring Bank Pharmaceuticals; Syndax Pharmaceuticals, Inc.; Tempest Therapeutics, Inc.; Vividion Therapeutics; and WntRx Pharmaceuticals Inc.
Grant/Research Support from AbbVie Inc.; Array BioPharma (Scientific Research Agreement; SRA); Boston Biomedical; Bristol-Myers Squibb; Celldex Therapeutics, Inc.; Checkmate Pharmaceuticals (SRA); Compugen Ltd.; Corvus Pharmaceuticals; EMD Serono, Inc.; Evelo Biosciences, Inc. (SRA); Delcath Systems Inc.; Five Prime Therapeutics, Inc.; Genentech, Inc.; Immunocore; Incyte Corporation; Leap Therapeutics, Inc.; MedImmune; MacroGenics, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pharmacyclics LLC; Palleon Pharmaceuticals (SRA); Tesaro, Inc.; and Xencor. (All Research Support to Institution Unless Noted.)
Other Financial or Material Support from TTC Oncology in the form of Data and Safety Monitoring Board. Travel from Array BioPharma; AstraZeneca; Benevir Biopharm Inc.; Bristol-Myers Squibb; Castle Biosciences, Inc.; Checkmate Pharmaceuticals; EMD Serono, Inc.; Ideaya Biosciences; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; NewLink Genetics Corporation; Novartis Pharmaceuticals Corporation; and Reflexion Pharmaceuticals, Inc. Patents: (both provisional) Serial #15/612,657 (Cancer Immunotherapy); PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof).

Jason J. Luke, MD, FACP, does not intend to discuss any non-FDA-approved or investigational use of any products/devices.

Jennifer Wargo, MD, MMSc
Associate Professor, Department of Surgical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Jennifer Wargo, MD, MMSc, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Biothera Pharmaceuticals; Bristol-Myers Squibb; F. Hoffmann-La Roche Ltd-Genentech, Inc.; GlaxoSmithKline; Merck Sharp & Dohme; MicrobiomeDx; and Novartis Pharmaceuticals Corporation.
Grant/Research Support from Bristol-Myers Squibb; F. Hoffmann-La Roche Ltd-Genentech, Inc.; GlaxoSmithKline; and Novartis Pharmaceuticals Corporation.
Speakers Bureau participant with Bristol-Myers Squibb; Dava Oncology; Gilead Sciences, Inc.; Illumina; Imedex; MedImmune; and Omniprex.
Other Financial or Material Support from US patent application (PCT/US17/53.717) submitted by the University of Texas MD Anderson Cancer Center that covers methods to enhance immune checkpoint blockade responses by modulating the microbiome.

Jennifer Wargo, MD, MMSc, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: including the neoadjuvant use of immune checkpoint inhibitors and BRAF/MEK targeting agents in malignant melanoma.

Faculty

Jennifer Tseng, MD
Assistant Professor of Surgery
Associate Program Director, General Surgery Residency
Associate Program Director, Complex General Surgical Oncology Fellowship
The University of Chicago
Chicago, Illinois

Jennifer Tseng, MD, has no financial interests/relationships or affiliations in relation to this activity.

Jennifer Tseng, MD, does not intend to discuss any non-FDA-approved or investigational use of any products/devices.

Content Reviewer

Siyang Leng, MD, has no financial interests/relationships or affiliations in relation to this activity.

Medical Directors

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Kristin Tomlinson, PhD
PVI, PeerView Institute for Medical Education

Kristin Tomlinson, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership


This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported through an educational grant from Bristol-Myers Squibb.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2019, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.